Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 4 of 4 entries
View as:
Phase: N/A
Priority: Normal
Start: 09/01/20
End: 08/31/23
Due: 08/31/24
Phase: N/A
Priority: Normal
Start: 08/20/19
End: 10/20/23
Due: 10/20/24
Phase: N/A
Priority: Normal
Start: 08/20/19
End: 06/30/21
Due: 06/30/22
Phase: N/A
Priority: Normal
Start: 07/01/23
End: 06/01/26
Due: 06/01/27
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| TC Plus PD-1 Inhibitors Combined With Anlotinib for Advanced Advanced Esophageal Cancer | NCT04471480 | Dong Wang | user2@example.com | None | 2020-09-01 | 2023-08-31 | 2024-08-31 | - | - | 2025-07-14 |
| Paclitaxel (Albumin-bound) and Oxaliplatin for Advanced Hepatobiliary and Malignant Tumors | NCT04060472 | Dong Wang | user2@example.com | None | 2019-08-20 | 2023-10-20 | 2024-10-20 | - | - | 2025-07-14 |
| Endostar/PD-1 Inhibitors Combined With PP for Advanced NSCLC | NCT04063449 | Dong Wang | user2@example.com | None | 2019-08-20 | 2021-06-30 | 2022-06-30 | - | - | 2025-07-14 |
| CIETAI and Sequential Radiotherapy in Squamous Lung Cancer | NCT05892237 | Dong Wang | user2@example.com | None | 2023-07-01 | 2026-06-01 | 2027-06-01 | - | - | 2025-07-14 |